<DOC>
	<DOC>NCT01680978</DOC>
	<brief_summary>A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 diabetes mellitus and no history of coronary artery disease who are drug-naïve or treated with stable metformin. Eligible patients will receive either 150 mcg aleglitazar or placebo orally daily for 6 weeks. After a washout period of 6 weeks, patients will cross over to the treatment not yet received.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Adult patients, 40 to 70 years of age (inclusive) at screening Patients with Type 2 diabetes mellitus diagnosed at least 12 weeks before screening and either drugnaïve or treated with stable metformin monotherapy for at least 12 weeks prior to screening HbA1c &gt;/= 7 % and &lt;/= 9% at screening Absence of history of coronary artery disease Diagnosis or history of Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes Current treatment with fibrates, thiazolidinediones, or insulin Prior intolerance to thiazolidinediones and/or fibrates Clinically significant liver disease or impaired liver function Know chronic diabetic complications (i.e. retinopathy, neuropathy, nephropathy) Symptomatic congestive heart failure classified as NYHA class IIIV Diagnosed and/or treated malignancy within the past 5 years, except for treated basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer Contraindications to MRI, or inability to tolerate MRI scanning</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>